The rnaz stock forecast shows bullish momentum, as RSI trends point toward a near-term breakout if institutional buying continues. Market watchers consider earnings updates and cash burn rates key to sustaining the rally in the rapidly shifting life sciences landscape. 2 days ago · RNAZ's current price target is $280.00. Learn why top analysts are making this stock forecast for TransCode Therapeutics at MarketBeat. According to the company’s press release , TransCode treated mice implanted with tumors derived from human glioblastoma multiforme (GBM) patients with TTX-MC138. Specifically, bioengineers delivered the therapeutic candidate directly to brain tumors. Following the delivery, researchers used magnetic resonance imaging (MRI) to determine if the treatment reached the tumors. rnaz stock forecast sentiment has firmed after management reaffirmed clinical trial timelines, bolstering investor confidence in projected revenue streams beginning next fiscal year.
